AU2004226430A1 - Muscarinic M1 receptor agonists for pain management - Google Patents

Muscarinic M1 receptor agonists for pain management Download PDF

Info

Publication number
AU2004226430A1
AU2004226430A1 AU2004226430A AU2004226430A AU2004226430A1 AU 2004226430 A1 AU2004226430 A1 AU 2004226430A1 AU 2004226430 A AU2004226430 A AU 2004226430A AU 2004226430 A AU2004226430 A AU 2004226430A AU 2004226430 A1 AU2004226430 A1 AU 2004226430A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
muscarinic
receptor
neuropathic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004226430A
Other languages
English (en)
Inventor
Robert R. Davis
Mario Rodriguez
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of AU2004226430A1 publication Critical patent/AU2004226430A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2004226430A 2003-03-28 2004-03-26 Muscarinic M1 receptor agonists for pain management Abandoned AU2004226430A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45904503P 2003-03-28 2003-03-28
US60/459,045 2003-03-28
PCT/US2004/009339 WO2004087158A2 (en) 2003-03-28 2004-03-26 Muscarinic m1 receptor agonists for pain management

Publications (1)

Publication Number Publication Date
AU2004226430A1 true AU2004226430A1 (en) 2004-10-14

Family

ID=33131858

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004226430A Abandoned AU2004226430A1 (en) 2003-03-28 2004-03-26 Muscarinic M1 receptor agonists for pain management

Country Status (13)

Country Link
US (1) US20050130961A1 (cg-RX-API-DMAC7.html)
EP (1) EP1613321A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006521399A (cg-RX-API-DMAC7.html)
KR (1) KR20050112116A (cg-RX-API-DMAC7.html)
CN (1) CN1777425A (cg-RX-API-DMAC7.html)
AU (1) AU2004226430A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409523A (cg-RX-API-DMAC7.html)
CA (1) CA2520125A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010171A (cg-RX-API-DMAC7.html)
NZ (1) NZ542690A (cg-RX-API-DMAC7.html)
RU (1) RU2358735C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004087158A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508733B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20080015225A1 (en) * 2004-07-16 2008-01-17 Janssen Pharmaceutica N.V. Dimeric Piperidine Derivatives
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2016513677A (ja) * 2013-03-15 2016-05-16 アカディア ファーマシューティカルズ インコーポレイテッド ムスカリンアゴニスト
ES2811088T3 (es) 2014-04-23 2021-03-10 Takeda Pharmaceuticals Co Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP2022523355A (ja) * 2019-02-22 2022-04-22 カルナ セラピューティックス，インコーポレイテッド 神経障害の処置のための重水素化キサノメリンの化合物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000030632A1 (en) * 1998-11-23 2000-06-02 Eisai Co., Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
TWI310035B (en) * 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists
RU2288919C2 (ru) * 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Производные бензимидазолидинона в качестве агентов мускариновых рецепторов
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists

Also Published As

Publication number Publication date
RU2358735C2 (ru) 2009-06-20
WO2004087158A2 (en) 2004-10-14
ZA200508733B (en) 2006-09-27
EP1613321A2 (en) 2006-01-11
JP2006521399A (ja) 2006-09-21
KR20050112116A (ko) 2005-11-29
WO2004087158A3 (en) 2005-03-31
BRPI0409523A (pt) 2006-04-18
NZ542690A (en) 2009-04-30
RU2005133197A (ru) 2006-04-27
MXPA05010171A (es) 2005-12-12
CN1777425A (zh) 2006-05-24
CA2520125A1 (en) 2004-10-14
US20050130961A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US20050130961A1 (en) Muscarinic M1 receptor agonists for pain management
KR920008703B1 (ko) 사람의 정신질환 치료용 제약학적 조성물
EP0604494B1 (en) 5-ht4 receptor antagonists
US5633382A (en) Histamine H3 -receptor antagonists and therapeutic uses thereof
US5486526A (en) Histamine H3 -receptor antagonists and therapeutic uses thereof
RU2333200C2 (ru) Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
CN1826115B (zh) 取代的哌啶化合物及其用法
HUT74949A (en) Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
US20180050018A1 (en) Peripheral-anticholinergic muscarinic agonist combination
IL149650A (en) Piperidine n-alkylcarboxylate compounds for use as medicaments for the treatment and prevention of ileus
RU2493851C2 (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств
EP1605939B1 (en) Pharmaceutical use of 1-azabicyclo¬ 2.2.2 octanes and a method of testing compounds for the ability of activating inactive wt p53
ES2307025T3 (es) Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
US20050228019A1 (en) Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
CA2238815A1 (en) Composition for treating pain
KR102040639B1 (ko) 히스타민-3 수용체 역효능제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
WO2014014698A2 (en) Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
GB2244431A (en) Treatment of age related memory impairment and other cognitive disorders
WO2022192252A1 (en) Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
ES2198136T3 (es) Empleo de derivados de tetrahidropiridinas (o 4-hidroxipiperidinas)-butilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
EP0709093A2 (en) Method for treating anxiety using an azabicyclic oxadiazole or thiadiazole compound
TW200533371A (en) Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
Le Bourdonnec et al. Novel trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles
AU2018215466A1 (en) Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof
CN110139650A (zh) 可卡因依赖症的治疗或防复发药

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application